Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about HNRNPA2B1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Gene Symbol | HNRNPA2B1 |
| Aliases | Page for HNRNPA2B1 |
| Chromosome | 7p15.2 |
| Protein Family | HnRNP A/B family |
| Protein Type | Other |
| Target Class | Other |
| Function | Therapeutic agents targeting HNRNPA2B1 would work by modulating its RNA-binding activity, preventing pathological protein aggregation, or reducing the formation of cytoplasmic inclusions associated... |
| Mechanism of Action | Therapeutic agents targeting HNRNPA2B1 would work by modulating its RNA-binding activity, preventing pathological protein aggregation, or reducing the formation of cytoplasmic inclusions associated with neurodegeneration. These drugs could utilize antisense oligonucleotides to reduce HNRNPA2B1 expression or small molecules to inhibit its protein-protein interactions and RNA-binding functions. |
| Druggability | Low (0.35) |
| Clinical Stage | Phase II |
| Molecular Weight | 36 kDa |
| Amino Acids | 341 aa |
| Pathways | RNA transport / hnRNP processing |
| UniProt ID | P22626 |
| NCBI Gene ID | 3181 |
| Ensembl ID | ENSG00000122566 |
| OMIM | 600124 |
| GeneCards | HNRNPA2B1 |
| Human Protein Atlas | HNRNPA2B1 |
| Associated Diseases | Als, Alzheimer's Disease, Amorphous Aggregates, Amyotrophic Lateral Sclerosis, Cancer |
| Known Drugs/Compounds | G-Quadruplex Structured Dna, Ionic Strength, Irinotecan, Single-Stranded Dna, Viral Genome G-Quadruplex |
| Interactions | Actin, ALZHEIMER, ALZHEIMER'S DISEASE, AND, App, C1Q |
| SciDEX Target | View Target Profile (1 clinical trials) |
| SciDEX Hypotheses | Axonal RNA Transport Reconstitution |
| KG Connections | 390 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
flowchart TD
HNRNPA2B1["HNRNPA2B1
RNA-binding protein
Ribonucleoprotein"]
%% RNA Processing & Associated Proteins
HNRNPA1["HNRNPA1
RNA-binding protein"]
IGF2BP1["IGF2BP1
RNA-binding protein"]
VALOSIN["VCP/VALOSIN
Protein processing"]
%% Signaling Pathways
NOTCH1["NOTCH1
Transcription factor"]
NotchPath["Notch Signaling
Pathway"]
CSNK2A1["CSNK2A1
Casein kinase"]
EpiPath["Epigenetic
Regulation"]
%% Neurodegenerative Diseases
ALS["Amyotrophic Lateral
Sclerosis (ALS)"]
FTD["Frontotemporal
Dementia"]
ALZ["Alzheimer's
Disease"]
MS["Multiple
Sclerosis"]
Dementia["Dementia
General"]
NeuroDegeneration["Neurodegeneration
Process"]
%% Inflammatory Process
Inflammation["Neuroinflammation
Process"]
%% Connections
HNRNPA2B1 -->|"associates with"| HNRNPA1
HNRNPA2B1 -->|"interacts with"| IGF2BP1
HNRNPA2B1 -->|"associates with"| VALOSIN
HNRNPA2B1 -->|"activates"| CSNK2A1
HNRNPA2B1 -->|"activates"| NOTCH1
HNRNPA2B1 -->|"activates"| NotchPath
HNRNPA2B1 -->|"inhibits"| EpiPath
HNRNPA2B1 -->|"activates"| ALS
HNRNPA2B1 -->|"activates"| ALZ
HNRNPA2B1 -->|"associated with"| FTD
HNRNPA2B1 -->|"activates"| MS
HNRNPA2B1 -->|"associated with"| Dementia
HNRNPA2B1 -->|"activates"| NeuroDegeneration
HNRNPA2B1 -->|"regulates"| Inflammation
Inflammation -->|"contributes to"| NeuroDegeneration
NotchPath -->|"promotes"| NeuroDegeneration
CSNK2A1 -->|"phosphorylates"| HNRNPA2B1
%% Styling
style HNRNPA2B1 fill:#006494
style HNRNPA1 fill:#4a1a6b
style IGF2BP1 fill:#4a1a6b
style VALOSIN fill:#4a1a6b
style NOTCH1 fill:#4a1a6b
style NotchPath fill:#ef5350
style CSNK2A1 fill:#4a1a6b
style EpiPath fill:#1b5e20
style ALS fill:#5d4400
style FTD fill:#5d4400
style ALZ fill:#5d4400
style MS fill:#5d4400
style Dementia fill:#5d4400
style NeuroDegeneration fill:#ef5350
style Inflammation fill:#ef5350| Target | Relation | Type | Str |
|---|---|---|---|
| Dynamic Liquid-Like Droplets | associated_with | phenotype | 0.95 |
| Rna Maturation | involved_in | process | 0.95 |
| liquid-liquid phase separation | associated_with | process | 0.95 |
| Rna Binding | involved_in | process | 0.95 |
| Liquid-Liquid Phase Separation | involved_in | process | 0.95 |
| RNA binding | involved_in | process | 0.95 |
| Mrna Transport | involved_in | process | 0.95 |
| GPX4 | associated_with | protein | 0.93 |
| dynamic liquid-like droplets | associated_with | phenotype | 0.92 |
| m6A methyladenosine reader | involved_in | mechanism | 0.92 |
| Protein Aggregation | contributes_to | process | 0.92 |
| protein aggregates | implicated_in | phenotype | 0.90 |
| intrinsically disordered domain | associated_with | phenotype | 0.90 |
| RNA binding | mediates | process | 0.90 |
| Pathogenic Protein Aggregates | associated_with | phenotype | 0.90 |
| RNA maturation | involved_in | process | 0.90 |
| mRNA transport | involved_in | process | 0.90 |
| Multisystem Proteinopathy | causes | disease | 0.90 |
| TAU | associated_with | protein | 0.90 |
| Intrinsically Disordered Low-Complexity Domain | associated_with | mechanism | 0.90 |
| G-Quadruplex Structured Dna | binds | compound | 0.90 |
| Membraneless Organelles | contributes_to | cell_type | 0.90 |
| Rna Recognition Domain | associated_with | protein | 0.90 |
| Nucleic Acid Metabolism | regulates | process | 0.90 |
| Ferroptosis | protects_against | process | 0.89 |
| pathogenic protein aggregates | associated_with | phenotype | 0.88 |
| Amorphous Aggregates | associated_with | phenotype | 0.88 |
| GPX4 | upregulates | gene | 0.87 |
| RNA Stress Granule | involved_in | process | 0.85 |
| membraneless organelles | contributes_to | cell_type | 0.85 |
| Tumorigenesis | involved_in | process | 0.85 |
| Low-Complexity Domain | interacts_with | biomarker | 0.85 |
| HSPA8 mRNA Dendritic Localization | regulates | process | 0.85 |
| Cancer | associated_with | disease | 0.85 |
| Tau Protein Toxicity | associated_with | phenotype | 0.85 |
| m6A reader | involved_in | protein | 0.85 |
| Viral Infection | involved_in | process | 0.85 |
| circEHD2 | regulates | gene | 0.85 |
| Mrnas In Gabaergic Neurons | regulates | biomarker | 0.85 |
| Cancer | implicated_in | disease | 0.85 |
| Hspa8 Mrna Localization | regulates | process | 0.85 |
| Rna Stress Granule Function | regulates | process | 0.85 |
| Single-Stranded Dna | binds | compound | 0.85 |
| Alzheimer's Disease | associated_with | disease | 0.80 |
| Cancer progression | contributes_to | process | 0.80 |
| GABAergic dysfunction | mediates | process | 0.80 |
| Tau Toxicity | associated_with | mechanism | 0.80 |
| Mrna Localization | involved_in | process | 0.80 |
| Nuclear Dna Sensing | mediates | process | 0.80 |
| DNAJB6 | associated_with | gene | 0.80 |
| Source | Relation | Type | Str |
|---|---|---|---|
| CBL | degrades | protein | 0.92 |
| Irinotecan | interacts_with | drug | 0.90 |
| h-8196b893 | targets | hypothesis | 0.90 |
| Irinotecan | binds | drug | 0.90 |
| LNK | regulates | protein | 0.90 |
| Irinotecan | interacts_with | drug | 0.90 |
| CBL | degrades | protein | 0.88 |
| CGG repeat RNA | binds | compound | 0.85 |
| Ph | modulates | compound | 0.85 |
| Cgg Repeat Rna | binds | variant | 0.85 |
| Ionic Strength | modulates | compound | 0.85 |
| LNK | promotes | protein | 0.85 |
| Camptothecin | binds | compound | 0.80 |
| Viral Genome G-Quadruplex | interacts_with | compound | 0.80 |
| Irinotecan | modulates | drug | 0.80 |
| Irinotecan | inhibits | drug | 0.75 |
| Irinotecan | inhibits | drug | 0.75 |
| RNA | inhibits | gene | 0.60 |
| RNA | regulates | gene | 0.60 |
| RNA | associated_with | gene | 0.60 |
| ALKBH5 | therapeutic_target | gene | 0.60 |
| RNA | therapeutic_target | gene | 0.60 |
| TNFRSF11B | activates | gene | 0.60 |
| CYTOKINES | activates | gene | 0.60 |
| SIRT6 | inhibits | gene | 0.60 |
| OPTN | associated_with | gene | 0.60 |
| RANK | activates | gene | 0.60 |
| RANKL | activates | gene | 0.60 |
| GAIN | activates | gene | 0.60 |
| HNRNPA1 | associated_with | gene | 0.60 |
| DNAJB6 | interacts_with | gene | 0.60 |
| TDP-43 | associated_with | gene | 0.60 |
| OPTINEURIN | associated_with | gene | 0.60 |
| RNA | degrades | gene | 0.60 |
| TAF15 | inhibits | gene | 0.60 |
| GENES | associated_with | gene | 0.60 |
| NOTCH1 | activates | gene | 0.60 |
| CSNK2A1 | activates | gene | 0.60 |
| GENES | causes | gene | 0.60 |
| FTO | therapeutic_target | gene | 0.60 |
| TAU | activates | gene | 0.60 |
| YES1 | activates | gene | 0.60 |
| SOX9 | activates | gene | 0.60 |
| ALS | associated_with | gene | 0.60 |
| HNRNPA1 | causes | entity | 0.60 |
| MATR3 | implicated_in | gene | 0.60 |
| JUN | activates | gene | 0.60 |
| DNAJB6 | interacts_with | protein | 0.60 |
| CD36 | regulates | gene | 0.60 |
| ATXN2 | associated_with | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Axonal RNA Transport Reconstitution | 0.695 | neurodegeneration | RNA binding protein dysregulation across |
| hnRNPA2B1-Mediated Structural Remodeling Controls lncRNA-002 | 0.684 | molecular neurobiology | View |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.720
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| s:** - Temporal analysis showing mitochondrial defects precede other p | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Proposed experiment from debate on TDP-43 undergoes liquid-liquid phas | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| s:** - Single-cell RNA-seq to measure editing efficiency across differ | falsification | ALS | 0.400 | 0.50 | cell_line | proposed | $150,000 |
| ALS Progression Rate Heterogeneity — mechanism and biomarker predictor | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| ALS Regional Onset and Spread: Network-Level Staging Model | clinical | ALS | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk Cohorts | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Axonal Transport Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Environmental Exposure Causal Attribution in ALS — Experiment Design | validation | ALS | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Frontal and Temporal Lobe Selective Vulnerability in FTD — Mechanisms | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,000,000 |
| FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| SIRT6-regulated macrophage efferocytosis epigenetically controls inflammation re [PMID:36593966] | Li B, Xin Z, Gao S, Li Y, Guo S, Fu Y, X | Theranostics | 2023 | 1 |
| Multisystem proteinopathy: Where myopathy and motor neuron disease converge. [PMID:33145792] | Korb MK, Kimonis VE, Mozaffar T | Muscle Nerve | 2021 | 1 |
| The role of m6A modification in the biological functions and diseases. [PMID:33611339] | Jiang X, Liu B, Nie Z, Duan L, Xiong Q, | Signal Transduct Target Ther | 2021 | 1 |
| Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liv [PMID:33213490] | Senlin Zhao, Yushuai Mi, Bingjie Guan, B | Journal of hematology & oncolo | 2020 | 1 |
| Rare Inherited forms of Paget's Disease and Related Syndromes. [PMID:30756140] | Ralston SH, Taylor JP | Calcif Tissue Int | 2019 | 1 |
| A LNK-CBL-HNRPA2B1-GPX4 signaling axis mediates dopaminergic neuron vulnerabilit [PMID:41616574] | ["Liu Z", "Wang R", "Shen M", "Lan X", " | Redox biology | 2026 | 0 |
| Human papillomavirus 16 E6 oncoprotein promotes up-regulation of RNA-binding pro [PMID:41725810] | ["Cerasuolo A", "Pecchillo Cimmino T", " | Frontiers in microbiology | 2026 | 0 |
| Molecular recognition and induced dimerization of hnRNP A2/B1 truncations by G-q [PMID:41888191] | ["Shahatibieke D", "Tang X", "Zheng X", | Scientific reports | 2026 | 0 |
| LncRNA 4930544M13Rik-201 regulates CACNA2D1 expression via interacting with hnRN [PMID:41864512] | Fang Z, Liu F, Tang Q, Liu Y, Peng Y, Zh | Brain research bulletin | 2026 | 0 |
| Comparative Binding Analysis by Computational Methods and Quartz Crystal Microba [PMID:41728844] | ["Volkova O", "Serova A", "Kravtsov V", | Journal of chemical informatio | 2026 | 0 |
| Functional Variants of the RAD51 Gene Contribute to Susceptibility to Non-Syndro [PMID:41918261] | Guo S, Guo T, Xu Y, Chen R, Wang X | Orthodontics & craniofacial re | 2026 | 0 |
| Ligand-specific conformational dynamics and interaction landscapes of hnRNPA2B1 [PMID:41853685] | Zhou Z, Li Y, Yang P, Zhu R, Li J, Wu B, | Current research in structural | 2026 | 0 |
| Neddylation-Mediated hnRNPA2B1 Degradation Aggravates Retinal Endothelial Cell D [PMID:41773772] | Chen TR, Zhou JX, Hou YR, Zhang YN, Li C | Investigative ophthalmology & | 2026 | 0 |
| Mechanistic studies on HNRNPA2B1 suggest binding but not selective recognition o [PMID:41662154] | ["Park R", "Demny M", "Miller L", "Pedra | RNA biology | 2026 | 0 |
| Network medicine modeling of the m⁶A regulatory landscape identifies a KLF6-WTAP [PMID:41787499] | Xu C, Zhou Z, Lin Y, Zhang S, Cai S, Li | Journal of translational medic | 2026 | 0 |
| Integrative transcriptome-wide association analyses reveal PRKCG-linked GABAergi [PMID:41507195] | ["Jin Y", "Cao Y", "Ma W", "Li R", "Li Y | Nature communications | 2026 | 0 |
| The Intersection of m6A Methylation and Immune Response in PCOS: A Bioinformatic [PMID:41725222] | ["Xu W", "Shi L", "Lu A", "Cui L", "Qian | Immunity, inflammation and dis | 2026 | 0 |
| Expression, purification, and biophysical characterization of liquid-liquid phas [PMID:41297573] | ["Dur\u00e1n-Armenta L", "Meszaros A", " | Protein expression and purific | 2026 | 0 |
| Interaction of tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progre [PMID:34453888] | Jiang L, Lin W, Zhang C, Ash PEA, Verma | Molecular cell | 2021 | 0 |
| Stress granule mediated protein aggregation and underlying gene defects in the F [PMID:31626953] | Baradaran-Heravi Y, Van Broeckhoven C, v | Neurobiology of disease | 2020 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.72 · 2026-04-12
closed · Rounds: 4 · Score: 0.88 · 2026-04-06
Hypotheses and analyses mentioning HNRNPA2B1 in their description or question text
No additional research found